Stockreport

ImmunityBio (IBRX) Is Down 5.8% After ANKTIVA Rollout Fuels Revenue Jump And Narrower Losses [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF largely by the commercial rollout of ANKTIVA and supported by positive interim data from its Phase 2 QUILT 2.005 bladder cancer trial. Alongside this earnings update, [Read more]